

Global Gaucher's Disease Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-16 | 147 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Gaucher's Disease Treatment Market Report and Forecast 2023-2031

Global Gaucher's Disease Treatment Market Outlook

The global Gaucher's disease treatment market size was valued at USD 1.5 billion in 2022 and is projected to grow at a CAGR of 3.6% during the forecast period of 2023-2031 to reach a value of USD 2.1 billion by 2031. The market growth can be attributed to the increasing prevalence of Gaucher's disease and the rising awareness about rare diseases and their treatments.

Global Gaucher's Disease Treatment Market: Introduction

Gaucher's disease is a rare genetic disorder caused by a deficiency of the enzyme glucocerebrosidase, leading to the accumulation of harmful substances in the body, primarily affecting the liver, spleen, bones, and bone marrow. The treatment options for Gaucher's disease include enzyme replacement therapy, substrate reduction therapy, and supportive care. Increasing prevalence of Gaucher's disease and growing awareness about rare diseases are driving the demand for Gaucher's disease treatment. Other factors such as government initiatives, advancements in medical technology, and the development of innovative treatment options are expected to drive market growth.

Advancements in technology have played a significant role in the growth of the Gaucher's disease treatment market. The introduction of enzyme replacement therapy and substrate reduction therapy has revolutionized the treatment landscape for Gaucher's disease, offering patients more effective and targeted treatment options. Additionally, ongoing research and development efforts in the field of gene therapy and chaperone therapy hold promise for the future treatment of Gaucher's disease. Efforts are underway to improve access to Gaucher's disease treatment globally and address unmet needs in the management of this rare disease.

Global Gaucher's Disease Treatment Market- Epidemiology

Gaucher's disease is estimated to affect approximately 1 in 50,000 to 1 in 100,000 people worldwide. The prevalence of the disease varies among different ethnic groups, with a notably higher prevalence among Ashkenazi Jews, where it affects approximately 1 in 800 individuals. Early diagnosis and access to appropriate treatment are crucial for improving the prognosis and quality of life for patients with Gaucher's disease.

Gaucher's Disease Treatment Market Segmentations

The market can be segmented based on indication type, therapy type, treatment type and major regions:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Market Breakup by indication Type

- Type 1 Gaucher's Disease
- Type 2 Gaucher's Disease
- Type 3 Gaucher's Disease

Market Breakup by Therapy Method

- Enzyme Replacement Therapy
- Substrate Reduction Therapy
- Splenectomy
- Orthopaedic Surgery
- Gene Therapy
- Others

Market Breakup by Treatment Channel

- Public
- Private

Market Breakup by Region

- North America
 - ?□United States of America
 - ?□Canada
- Europe
 - ?□United Kingdom
 - ?□Germany
 - ?□France
 - ?□Italy
 - ?□Others
- Asia Pacific
 - ?□China
 - ?□Japan
 - ?□India
 - ?□ASEAN
 - ?□Australia
 - ?□Others
- Latin America
 - ?□Brazil
 - ?□Argentina
 - ?□Mexico
 - ?□Others
- Middle East and Africa
 - ?□Saudi Arabia
 - ?□United Arab Emirates
 - ?□Nigeria
 - ?□South Africa
 - ?□Others

Gaucher's Disease Treatment Market Analysis

The global Gaucher's disease treatment market has experienced significant growth over the past few years, driven by factors such as increasing prevalence of Gaucher's disease, rising awareness about rare diseases, advancements in medical technology, and the development of innovative treatment options. One key driver of growth in the Gaucher's disease treatment market is the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

increasing focus on research and development in the field of rare diseases.

North America is currently the largest market for Gaucher's disease treatment, accounting for a significant share of the global market. The region's large market share is driven by factors such as a high prevalence of Gaucher's disease, a well-established healthcare infrastructure, and strong investment in research and development for rare diseases. In addition, the availability of advanced treatment options, such as enzyme replacement therapy and substrate reduction therapy, is further driving the growth of the market in North America.

Europe is also a significant market for Gaucher's disease treatment, with countries such as the United Kingdom, Germany, and France leading the way. The region's market growth is driven by factors such as a large population base, increasing awareness of rare diseases, and government initiatives to address the needs of patients with rare diseases. Additionally, the region has a well-established healthcare system, which supports the delivery of Gaucher's disease treatment.

Asia Pacific is another region that is experiencing significant growth in the Gaucher's disease treatment market. The region's market growth is driven by factors such as a large population base, increasing awareness of rare diseases, and the growing adoption of advanced treatment options. In addition, government initiatives to address the needs of patients with rare diseases are helping to drive the growth of the market in the region.

Key Players in the Global Gaucher's Disease Treatment Market

The report provides a detailed analysis of the key players involved in the Gaucher's disease treatment market, including their business overview, product portfolio, recent developments, and financial analysis. Some of the major players operating in the market include:

- [] Genzyme (Sanofi S.A.)
- [] Amicus Therapeutics, Inc.
- [] Novartis AG
- [] Shire plc
- [] Actelion Pharmaceuticals Ltd.
- [] Protalix Bio Therapeutics Inc.
- [] Johnson & Johnson
- [] Takeda Pharmaceutical Company Limited
- [] Abbott Laboratories
- [] Aptalis Pharma Inc.
- [] GSK plc

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
- 2 Research Methodology
- 3 Executive Summary
- 4 Gaucher's Disease Overview
 - 4.1 Guidelines and Stages
 - 4.2 Pathophysiology
 - 4.3 Screening and Diagnosis
 - 4.4 Treatment Pathway
- 5 Patient Profile
 - 5.1 Patient Profile Overview
 - 5.2 Patient Psychology and Emotional Impact Factors
 - 5.3 Risk Assessment and Treatment Success Rate
- 6 Current Scenario Evaluation and Regulatory Framework

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1 Emerging Therapies and Clinical Trials
- 6.2 Patent Landscape
 - 6.2.1 Patent Overview
 - 6.2.1.1 Patent Status and Expiry
 - 6.2.1.2 Timelines from Drug Development to Commercial Launch
 - 6.2.1.3 New Drug Application
 - 6.2.1.3.1 Documentation and Approval Process
- 6.3 Cost of Treatment
- 6.4 Regulatory Framework
 - 6.4.1 Regulatory Overview
 - 6.4.1.1 US FDA
 - 6.4.1.2 EU EMA
 - 6.4.1.3 INDIA CDSCO
 - 6.4.1.4 JAPAN PMDA
 - 6.4.1.5 Others
- 7 Challenges and Unmet Needs
 - 7.1 Treatment Pathway Challenges
 - 7.2 Compliance and Drop-Out Analysis
 - 7.3 Awareness and Prevention Gaps
- 8 Global Gaucher's Disease Treatment Market
 - 8.1 Global Gaucher's Disease Treatment Market Overview
 - 8.2 Global Gaucher's Disease Treatment Market Analysis
 - 8.2.1 Market Overview
 - 8.2.1.1 Global Gaucher's Disease Treatment Market Historical Value (2016-2022)
 - 8.2.1.2 Global Gaucher's Disease Treatment Market Forecast Value (2023-2031)
 - 8.3 Global Gaucher's Disease Treatment Market by Indication Type
 - 8.3.1 Market Overview
 - 8.3.1.1 Type 1 Gaucher's Disease
 - 8.3.1.2 Type 2 Gaucher's Disease
 - 8.3.1.3 Type 3 Gaucher's Disease
 - 8.4 Global Gaucher's Disease Treatment Market by Therapy Method
 - 8.4.1 Market Overview
 - 8.4.1.1 Enzyme Replacement Therapy
 - 8.4.1.2 Substrate Reduction Therapy
 - 8.4.1.3 Splenectomy
 - 8.4.1.4 Orthopedic Surgery
 - 8.4.1.5 Gene Therapy
 - 8.4.1.6 Others
 - 8.5 Global Gaucher's Disease Treatment Market by Treatment Channel
 - 8.5.1 Market Overview
 - 8.5.1.1 Public
 - 8.5.1.2 Private
 - 8.6 Global Gaucher's Disease Treatment Market by Region
 - 8.6.1 Market Overview
 - 8.6.1.1 North America
 - 8.6.1.2 Europe
 - 8.6.1.3 Asia Pacific

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.6.1.4 Middle East and Africa
 - 8.6.1.5 Latin America
- 9 North America Gaucher's Disease Treatment Market
 - 9.1 Market Share by Country
 - 9.2 United States of America
 - 9.2.1 Historical Trend (2016-2022)
 - 9.2.2 Forecast Trend (2023-2031)
 - 9.3 Canada
 - 9.3.1 Historical Trend (2016-2022)
 - 9.3.2 Forecast Trend (2023-2031)
- 10 Europe Gaucher's Disease Treatment Market
 - 10.1 Market Share by Country
 - 10.2 United Kingdom
 - 10.2.1 Historical Trend (2016-2022)
 - 10.2.2 Forecast Trend (2023-2031)
 - 10.3 Germany
 - 10.3.1 Historical Trend (2016-2022)
 - 10.3.2 Forecast Trend (2023-2031)
 - 10.4 France
 - 10.4.1 Historical Trend (2016-2022)
 - 10.4.2 Forecast Trend (2023-2031)
 - 10.5 Italy
 - 10.5.1 Historical Trend (2016-2022)
 - 10.5.2 Forecast Trend (2023-2031)
 - 10.6 Others
- 11 Asia Pacific Gaucher's Disease Treatment Market
 - 11.1 Market Share by Country
 - 11.2 China
 - 11.2.1 Historical Trend (2016-2022)
 - 11.2.2 Forecast Trend (2023-2031)
 - 11.3 Japan
 - 11.3.1 Historical Trend (2016-2022)
 - 11.3.2 Forecast Trend (2023-2031)
 - 11.4 India
 - 11.4.1 Historical Trend (2016-2022)
 - 11.4.2 Forecast Trend (2023-2031)
 - 11.5 ASEAN
 - 11.5.1 Historical Trend (2016-2022)
 - 11.5.2 Forecast Trend (2023-2031)
 - 11.6 Australia
 - 11.6.1 Historical Trend (2016-2022)
 - 11.6.2 Forecast Trend (2023-2031)
 - 11.7 Others
- 12 Latin America Gaucher's Disease Treatment Market
 - 12.1 Market Share by Country
 - 12.2 Brazil
 - 12.2.1 Historical Trend (2016-2022)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2.2 Forecast Trend (2023-2031)
 - 12.3 Argentina
 - 12.3.1 Historical Trend (2016-2022)
 - 12.3.2 Forecast Trend (2023-2031)
 - 12.4 Mexico
 - 12.4.1 Historical Trend (2016-2022)
 - 12.4.2 Forecast Trend (2023-2031)
 - 12.5 Others
- 13 Middle East and Africa Gaucher's Disease Treatment Market
 - 13.1 Market Share by Country
 - 13.2 Saudi Arabia
 - 13.2.1 Historical Trend (2016-2022)
 - 13.2.2 Forecast Trend (2023-2031)
 - 13.3 United Arab Emirates
 - 13.3.1 Historical Trend (2016-2022)
 - 13.3.2 Forecast Trend (2023-2031)
 - 13.4 Nigeria
 - 13.4.1 Historical Trend (2016-2022)
 - 13.4.2 Forecast Trend (2023-2031)
 - 13.5 South Africa
 - 13.5.1 Historical Trend (2016-2022)
 - 13.5.2 Forecast Trend (2023-2031)
 - 13.6 Others
- 14 Global Gaucher's Disease Treatment Market Dynamics
 - 14.1 Market Drivers and Constraints
 - 14.2 SWOT Analysis
 - 14.3 Porter's Five Forces Model
 - 14.4 Key Demand Indicators
 - 14.5 Key Price Indicators
 - 14.6 Industry Events, Initiatives, and Trends
 - 14.7 Value Chain Analysis
- 15 Supplier Landscape
 - 15.1 Genzyme (Sanofi S.A.)
 - 15.1.1 Company Overview
 - 15.1.2 Product Portfolio
 - 15.1.3 Demographic Reach and Achievements
 - 15.1.4 Mergers and Acquisitions
 - 15.1.5 Certifications
 - 15.2 Amicus Therapeutics, Inc.
 - 15.2.1 Company Overview
 - 15.2.2 Product Portfolio
 - 15.2.3 Demographic Reach and Achievements
 - 15.2.4 Mergers and Acquisitions
 - 15.2.5 Certifications
 - 15.3 Novartis AG
 - 15.3.1 Company Overview
 - 15.3.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Shire plc
 - 15.4.1 Company Overview
 - 15.4.2 Product Portfolio
 - 15.4.3 Demographic Reach and Achievements
 - 15.4.4 Mergers and Acquisitions
 - 15.4.5 Certifications
- 15.5 Actelion Pharmaceuticals Ltd.
 - 15.5.1 Company Overview
 - 15.5.2 Product Portfolio
 - 15.5.3 Demographic Reach and Achievements
 - 15.5.4 Mergers and Acquisitions
 - 15.5.5 Certifications
- 15.6 Protalix Bio Therapeutics Inc.
 - 15.6.1 Company Overview
 - 15.6.2 Product Portfolio
 - 15.6.3 Demographic Reach and Achievements
 - 15.6.4 Mergers and Acquisitions
 - 15.6.5 Certifications
- 15.7 Johnson & Johnson
 - 15.7.1 Company Overview
 - 15.7.2 Product Portfolio
 - 15.7.3 Demographic Reach and Achievements
 - 15.7.4 Mergers and Acquisitions
 - 15.7.5 Certifications
- 15.8 Takeda Pharmaceutical Company Limited
 - 15.8.1 Company Overview
 - 15.8.2 Product Portfolio
 - 15.8.3 Demographic Reach and Achievements
 - 15.8.4 Mergers and Acquisitions
 - 15.8.5 Certifications
- 15.9 Abbott Laboratories
 - 15.9.1 Company Overview
 - 15.9.2 Product Portfolio
 - 15.9.3 Demographic Reach and Achievements
 - 15.9.4 Mergers and Acquisitions
 - 15.9.5 Certifications
- 15.10 Aptalis Pharma Inc.
 - 15.10.1 Company Overview
 - 15.10.2 Product Portfolio
 - 15.10.3 Demographic Reach and Achievements
 - 15.10.4 Mergers and Acquisitions
 - 15.10.5 Certifications
- 15.11 GSK plc
 - 15.11.1 Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and Acquisitions
- 15.11.5 Certifications
- 16 Global Gaucher's Disease Treatment Market- Drug Distribution Model (Additional Insight)
 - 16.1 Overview
 - 16.2 Potential Distributors
 - 16.3 Key Parameters for Distribution Partner Assessment
- 17 Payment Methods (Additional Insight)
 - 17.1 Government Funded
 - 17.2 Private Insurance
 - 17.3 Out-of-Pocket

Global Gaucher's Disease Treatment Market Report and Forecast 2023-2031

Market Report | 2023-04-16 | 147 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-15"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com